US Bancorp’s ImmunityBio IBRX Stock Holding History

US Bancorp’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$137K	Buy	15,641 +5,140	+49%	+$38.9K	﹤0.01%	2294
2026 Q1	$80.5K	Buy	10,501 +8,501	+425%	+$58.2K	﹤0.01%	2495
2025 Q4	$3.96K	Hold	2,000	–	–	﹤0.01%	3613
2025 Q3	$4.92K	Hold	2,000	–	–	﹤0.01%	3549
2025 Q2	$5.28K	Sell	2,000 -791	-28%	-$2.13K	﹤0.01%	3619
2025 Q1	$8.4K	Buy	+2,791	New	+$8.46K	﹤0.01%	3496
2023 Q4	–	Sell	-1,710	Closed	-$2.89K	–	4054
2023 Q3	$2.89K	Hold	1,710	–	–	﹤0.01%	3583
2023 Q2	$4.75K	Buy	1,710 +487	+40%	+$1.38K	﹤0.01%	3491
2023 Q1	$2.23K	Buy	1,223 +87	+8%	+$271	﹤0.01%	3733
2022 Q4	$5.76K	Buy	1,136 +812	+251%	+$4.46K	﹤0.01%	3467
2022 Q3	$2K	Hold	324	–	–	﹤0.01%	3834
2022 Q2	$1K	Hold	324	–	–	﹤0.01%	3961
2022 Q1	$2K	Sell	324 -262	-45%	-$1.61K	﹤0.01%	3830
2021 Q4	$4K	Sell	586 -2,000	-77%	-$15K	﹤0.01%	3713
2021 Q3	$25K	Sell	2,586 -1,398	-35%	-$15.4K	﹤0.01%	3013
2021 Q2	$57K	Hold	3,984	–	–	﹤0.01%	2612
2021 Q1	$95K	Hold	3,984	–	–	﹤0.01%	2300
2020 Q4	$53K	Buy	3,984 +984	+33%	+$9.46K	﹤0.01%	2491
2020 Q3	$21K	Sell	3,000 -2,000	-40%	-$19.9K	﹤0.01%	2798
2020 Q2	$61K	Buy	5,000 +3,000	+150%	+$16.9K	﹤0.01%	2341
2020 Q1	$6K	Buy	+2,000	New	+$10K	﹤0.01%	3189

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

US Bancorp's IBRX Position: Q2 2026 in Review

US Bancorp increased its ImmunityBio (IBRX) stake by 49% in Q2 2026, buying an estimated $38.9K and bringing the position to 15,641 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #2294.

US Bancorp first reported a position in IBRX in Q1 2020 and has held it in 21 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

US Bancorp held 15,641 shares of ImmunityBio worth $137K as of Q2 2026.
US Bancorp bought 5,140 ImmunityBio shares in Q2 2026, an estimated $38.9K.
ImmunityBio made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2294 holding.
US Bancorp first reported a position in ImmunityBio in Q1 2020 and has held it in 21 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.